Mark Oshaughnessy, MD
Cardiovascular Disease · Fort Wayne, INNPI 1962494138
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by United Therapeutics Corporation at 35.0% of the total. Reporting peaked in 2019 at $189 and has fallen 76.1% since, to $45 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in IN, where the typical reported total is $2,452.
Across 24 payments — averaging $32.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$277
- Actelion Pharmaceuticals US, Inc.$132
- Heartflow, Inc.$86
- Johnson & Johnson$85
- Telix Pharmaceuticals$48
- Edwards Lifesciences$44
- plus $118 from 7 others
Across 21 payments — averaging $7987.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$132K
- Janssen Research & Development, LLC$36K
What the payments were for
- Food & beverage$77898%
- Education$132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 8 | $277 |
| Actelion Pharmaceuticals US, Inc. | 1 | $132 |
| Heartflow, Inc. | 1 | $86 |
| Johnson & Johnson | 5 | $85 |
| Telix Pharmaceuticals | 1 | $48 |
| Edwards Lifesciences | 1 | $44 |
| Kyowa Kirin, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Merck | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Biotronik Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$791 in reported general payments places this provider in the 30th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 680 | $830,810 |
| OpsumitMacitentan | 40 | $500,827 |
| UptraviSelexipag | 24 | $477,150 |
| Orenitram ErTreprostinil Diolamine | 44 | $431,089 |
| EntrestoSacubitril/Valsartan | 151 | $209,536 |
| XareltoRivaroxaban | 153 | $181,592 |
| JardianceEmpagliflozin | 83 | $99,149 |
| Repatha SureclickEvolocumab | 58 | $48,495 |
| Ambrisentan | 21 | $37,253 |
| Bosentan | 33 | $36,089 |
| Praluent PenAlirocumab | 36 | $28,831 |
| FarxigaDapagliflozin Propanediol | 16 | $14,315 |
| VascepaIcosapent Ethyl | 13 | $11,931 |
| Torsemide | 407 | $10,108 |
| Metoprolol Succinate | 758 | $8,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Bosentan | $132 | $1,014,06797 claims |
| NovartisEntresto | $14 | $209,536151 claims |
| Johnson & JohnsonXarelto | $85 | $181,592153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Fort Wayne
- Michael MirroFort Wayne$57K
- Louis LopezFort Wayne$36K
- Issa KutkutFort Wayne$18K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.